Fovista: Ph III OPH1002 data

The double-blind, sham-controlled, international Phase III OPH1002 trial in 619 patients with wet AMD showed that intravitreal injections of 1.5 mg Fovista plus 0.5 mg

Read the full 250 word article

User Sign In